*  Iopamidol-300 / iopamidol NDA 074638 global drug patent coverage, generic alternatives and suppliers
Additional details are available on the IOPAMIDOL-300 profile page. The generic ingredient in IOPAMIDOL-300 is iopamidol. There ... NDA 074638 describes IOPAMIDOL-300, which is a drug marketed by Abbvie, Cook Imaging, Fresenius Kabi Usa, and Hospira, and is ...
  https://www.drugpatentwatch.com/p/NDA/074638
*  American Pharmaceutical Partners Inc. Recalls Iopamidol-300
Iopamidol-300 (Iopamidol Injection, USP) 61%, 150 mL in a 200 mL vial, Single Dose, Rx for intravascular use for angiography ... Recalls Iopamidol-300. Melrose Park, IL (SafetyAlerts) - The Food and Drug Administration (FDA) said today that American ... is recalling certain lots of its Iopamidol-300 because of a lack of efficacy. ...
  http://www.safetyalerts.com/f/00/d0011.html
*  Iopamidol - Wikipedia
Iopamidol (INN, tradenames Iopamiro, Isovue, Iopamiron, and Niopam) is a nonionic, low-osmolar iodinated contrast agent, ... Iopamidol is primarily used in the following: Angiography throughout the cardiovascular system, including cerebral and ... April 2004). "Iopamidol (Isovue) prescribing information (revised April 2004)". DailyMed. U.S. National Library of Medicine. ...
  https://en.wikipedia.org/wiki/Iopamidol
*  March 2018 - When will the patents on IOPAMIDOL-200 IN PLASTIC CONTAINER expire, and when will generic IOPAMIDOL-200 IN PLASTIC...
IOPAMIDOL-200 IN PLASTIC CONTAINER. iopamidol. INJECTABLE;INJECTION. 074636-001. Dec 30, 1997. DISCN. No. No. ➠ Sign Up. ➠ Sign ... IOPAMIDOL-200 IN PLASTIC CONTAINER Drug Profile. « Back to Dashboard. Which patents cover Iopamidol-200 In Plastic Container, ... The generic ingredient in IOPAMIDOL-200 IN PLASTIC CONTAINER is iopamidol. There are eleven drug master file entries for this ... and when can generic versions of Iopamidol-200 In Plastic Container launch?. Iopamidol-200 In Plastic Container is a drug ...
  https://www.drugpatentwatch.com/p/tradename/IOPAMIDOL-200+IN+PLASTIC+CONTAINER
*  ISOVUE-M 300 (Iopamidol) dosage, indication, interactions, side effects | EMPR - Cancer Therapy Advisor
Iopamidol) drug information & product resources from MPR including dosage information, educational materials, & patient ... Iopamidol 612mg/mL; soln for intrathecal administration; contains sodium 0.043mg, organically bound iodine 300mg per mL. ...
  https://www.cancertherapyadvisor.com/isovue-m-300/drug/4017/
*  2-Iodoamphetamine (hydrochloride)- CAS Number 22080-10-0
Iopamidol. 10 mg. LGCFOR0838.00. In den Warenkorb Iopydol. 5 mg. LGCFOR3117.00. In den Warenkorb ...
  https://www.lgcstandards.com/DE/de/2-Iodoamphetamine-hydrochloride-/p/CAY-9001851-5MG
*  List of Endoscopy or Radiology Premedication Medications (55 Compared) - Drugs.com
Generic name: iopamidol systemic Brand names: Isovue-370, Isovue-300, Isovue-200, Isovue-250, Isovue-M-200, Isovue-M-300 … ...
  https://www.drugs.com/condition/endoscopy-or-radiology-premedication.html
*  Repaglinide And Metformin (Oral Route) Proper Use - Mayo Clinic
Under certain conditions, too much metformin and repaglinide can cause lactic acidosis. Symptoms of lactic acidosis are severe and quick to appear and usually occur when other health problems not related to the medicine are present and are very severe, such as a heart attack or kidney failure. Call your doctor right away if you have abdominal or stomach discomfort; decreased appetite; diarrhea; fast, shallow breathing; general feeling of discomfort; muscle pain or cramping; nausea; or unusual sleepiness, tiredness, or weakness .. Radiologic procedures (e.g., x-rays, CT scans, and MRIs) that use intravenous contrast media can cause kidney problems and lactic acidosis in people who take metformin. Use of this medicine should be discontinued before you have one of these procedures. The medicine should not be started again during the 48 hours after the procedure. You may begin taking your medicine again after the doctor checks your kidneys for normal function Use of this medicine should be stopped ...
  https://www.mayoclinic.org/drugs-supplements/repaglinide-and-metformin-oral-route/proper-use/DRG-20071990?p=1
*  Metformin (Oral Route) Before Using - Mayo Clinic
Under certain conditions, too much metformin can cause lactic acidosis. The symptoms of lactic acidosis are severe and quick to appear, and usually occur when other health problems not related to the medicine are present and are very severe, such as a heart attack or kidney failure. Symptoms of lactic acidosis include abdominal or stomach discomfort, decreased appetite; diarrhea; fast or shallow breathing; a general feeling of discomfort; severe muscle pain or cramping; and unusual sleepiness, tiredness, or weakness. If symptoms of lactic acidosis occur, you should get immediate emergency medical help. Metformin can cause low blood sugar (hypoglycemia). However, this can also occur if you delay or miss a meal or snack, drink alcohol, exercise more than usual, cannot eat because of nausea or vomiting, take certain medicines, or take metformin with another type of diabetes medicine. The symptoms of low blood sugar must be treated before they lead to unconsciousness (passing out). Different people ...
  https://www.mayoclinic.org/drugs-supplements/metformin-oral-route/before-using/DRG-20067074?p=1
*  Saxagliptin And Metformin (Oral Route) Proper Use - Mayo Clinic
Under certain conditions, too much metformin can cause a condition called lactic acidosis. The symptoms of lactic acidosis are severe, appear quickly, and usually occur when other health problems are present, such as a heart attack or kidney failure. Symptoms of lactic acidosis include abdominal or stomach discomfort, decreased appetite, diarrhea, fast or shallow breathing, a general feeling of discomfort, muscle pain or cramping, and unusual sleepiness, tiredness, or weakness. If symptoms of lactic acidosis occur, you should get immediate emergency medical help. Pancreatitis (swelling and inflammation of the pancreas) may occur while you are using this medicine. Check with your doctor right away if you have sudden and severe stomach pain, chills, constipation, nausea, vomiting, fever, or lightheadedness. If you are rapidly gaining weight, having shortness of breath, chest pain, extreme tiredness or weakness, irregular breathing, irregular heartbeat, or excessive swelling of the hands, wrist, ...
  https://www.mayoclinic.org/drugs-supplements/saxagliptin-and-metformin-oral-route/proper-use/DRG-20074625?p=1
*  Pioglitazone And Metformin (Oral Route) Before Using - Mayo Clinic
Let your doctor or dentist know you are taking this medicine. Your doctor may advise you to stop taking this medicine before you have major surgery or diagnostic tests, especially tests that use a contrast dye. Under certain conditions, too much metformin can cause a serious condition called lactic acidosis. The symptoms of lactic acidosis are severe and appear quickly. Lactic acidosis usually occurs when other serious health problems are present, such as a heart attack or kidney failure. The symptoms of lactic acidosis include: abdominal or stomach discomfort; decreased appetite; diarrhea; fast or shallow breathing; a general feeling of discomfort; muscle pain or cramping; and unusual sleepiness, tiredness, or weakness. If you have more than one of these symptoms together, you should get immediate emergency medical help. Tell your doctor right away if you have any of these symptoms: loss of appetite, nausea, vomiting, stomach pain, unusual tiredness or weakness, weight loss, or yellow eyes or ...
  https://www.mayoclinic.org/drugs-supplements/pioglitazone-and-metformin-oral-route/before-using/drg-20063126?p=1
*  Kidney Damage in Patients With Moderate Fall in eGFR - Full Text View - ClinicalTrials.gov
... as a New Bio-Marker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL ...
  https://clinicaltrials.gov/ct2/show/NCT01136876
*  Radiology - Drugs| Medindia
Iopamidol Non-ionic Iodinated Contrast Media Ioversol. Non-ionic Iodinated Contrast Media ...
  http://www.medindia.net/drugs/speciality/radiology.htm
*  Castor Oil, Balsam Peru, and Trypsin Topical Products Drug Shortage Notice - Drugs.com
Iopamidol Injection - Resolved. *Levothyroxine (Levothroid) Oral Tablets - No Longer Available. *Otic Unapproved Prescription ...
  https://www.drugs.com/drug-shortages/castor-oil-balsam-peru-and-trypsin-topical-products-1179
*  Adverse Reactions to Contrast Material. Recognition, Prevention and Treatment - American Family Physician
Adverse reactions to contrast agents range from a mild inconvenience, such as itching associated with hives, to a life-threatening emergency. Renal toxicity is a well known adverse reaction associated with the use of intravenous contrast material. Other forms of adverse reactions include delayed allergic reactions, anaphylactic reactions, and local tissue damage. Previous allergic reactions to contrast material, asthma, and allergies are factors associated with an increased risk of developing an adverse reaction. Pretreatment of patients who have such risk factors with a corticosteroid and diphenhydramine decreases the chance of allergic reactions, including anaphylaxis, renal failure, or a possible life-threatening emergency. Awareness of the different types of risk factors and prescreening for their presence allows for early recognition and prompt treatment. Prophylactic treatment before administration of contrast material can prevent potential adverse reactions. If such reactions do occur, prompt
  https://www.aafp.org/afp/2002/1001/p1229.html
*  Metformin
... is one of the most commonly used drugs in the world and has earned its place as the first medication to prescribe for type 2 diabetes and those with type 1 who have insulin resistance. It is effective, inexpensive and has limited side effects. You can read more about why in this 2013 study. Metformin is in a class of drugs called biguanides. It significantly lowers blood sugar for most people. Studied in human since the 1950s, it has a very strong track record of safety and improved outcomes. Side effects tend to be minimal and temporary, though there is a minority of people who do not tolerate it well. It does not cause weight gain or low blood sugars. In This Section1 Brand Names for Metformin2 Brand Names for Metformin in Combination with Other Drugs3 How Does Metformin Work?4 Precautions Before Taking Metformin5 Side Effects of Metformin6 How to Take
  https://www.diabetesdaily.com/learn-about-diabetes/overview-of-diabetes-drugs/metformin/
*  Arterial supply to the pancreas; variations and cross-sectional anatomy.
Iopamidol / diagnostic use. Male. Middle Aged. Pancreas / blood supply*. Pancreatic Diseases / etiology, radiography*. ...
  http://www.biomedsearch.com/nih/Arterial-supply-to-variations-cross/19777288.html
*  Drug Summary
Iopamidol: (Moderate) Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk for nephrotoxicity when given to ...
  http://www.pdr.net/drug-summary/Cambia-diclofenac-potassium-2426
*  Caffeine Citrate (caffeine citrate) dose, indications, adverse effects, interactions... from PDR.net
Iopamidol: (Major) Use of medications that lower the seizure threshold should be carefully evaluated when considering ...
  http://www.pdr.net/drug-summary/Caffeine-Citrate-caffeine-citrate-3724
*  Hush Puppies Collection
iopamidol injection) is a safe and effective ... clinical experience since 1986. Worldwide, more ... been administered. ... is a formulation of iopamidol in ... oral administration or, where necessary, by ... improvement in the radiological ...
  http://www.bio-medicine.org/medicine-products/Hush-Puppies-Collection-25910-1/
*  Leica L-55 Style Surgical Microscope Video Adapter from ImagingPlanet
iopamidol injection) is a safe and effective ... clinical experience since 1986. Worldwide, more ... been administered. ... is a formulation of iopamidol in ... oral administration or, where necessary, by ... improvement in the radiological ...
  http://www.bio-medicine.org/medicine-products/Leica-L-55-Style-Surgical-Microscope-Video-Adapter-from-ImagingPlanet-15706-1/
*  Isovue Side Effects
Isovue (iopamidol injection) Pre-Filled Power Injector Syringes by Bracco Diagnostics Inc.: Recall - Presence of Particulates. ... BDI) is voluntarily initiating a Class I recall of nine (9) lots of Isovue (iopamidol injection) Pre-Filled Power Injector ...
  http://patientsville.com/medication/isovue_side_effects.htm

(1/131) Elimination of iomeprol in patients undergoing continuous ambulatory peritoneal dialysis.

OBJECTIVE: To examine the elimination of iomeprol, its safety in clinical use, and its peritoneal permeability in continuous ambulatory peritoneal dialysis (CAPD) patients with variable degrees of residual renal function (RRF). DESIGN: A nonrandomized comparison study. SETTING: Hospitalized patients in CAPD unit of Chikuho and University Hospitals. PARTICIPANTS: Fourteen patients treated by CAPD and 6 by hemodialysis (HD). INTERVENTIONS: Total dialysate, blood, and 24-hour urine collections were obtained for 4 consecutive days after the administration of iomeprol. A peritoneal equilibration test was performed just before and after the administration of iomeprol. MEASUREMENTS: Iomeprol (iodine) concentration was measured. Residual renal function was estimated as the mean of renal creatinine and urea clearances. Dialysate-to-plasma ratios (D/P) of creatinine and iomeprol were also determined. RESULTS: In all CAPD patients, plasma iomeprol clearance was markedly slow, with a biological half-life (T1/2) of over 32 hours. However, no patients suffered from any adverse effects, and over 80% of plasma iomeprol was eliminated during the 4-hour HD. The plasma iomeprol elimination rate was significantly higher from 4 hours after the iomeprol administration in CAPD patients with RRF [mean estimated creatinine clearance (CCr) 3.8 mL/min, n = 7] compared to the remaining patients (mean estimated CCr 0.6 mL/min, n = 7); however, T1/2 in patients with RRF was over 24 hours. D/P creatinine was significantly correlated with D/P iomeprol, and peritoneal iomeprol permeability may depend on an individual's peritoneal solute transport properties. CONCLUSIONS: A prolonged elimination rate of iomeprol was documented in our CAPD patients both with and without RRF. A HD procedure or intensive peritoneal dialysis just after the use of iomeprol may be advisable to promptly remove circulating iomeprol.  (+info)

(2/131) Abdominal aortic aneurysm measurements for endovascular repair: intra- and interobserver variability of CT measurements.

OBJECTIVES: to evaluate the intra- and interobserver variability in measurements of the aorta and iliac arteries in patients with abdominal aortic aneurysms (AAAs) considered for endovascular repair using computed tomography angiography (CTA). METHODS: the diameter of the neck, aneurysm, right and left iliac artery were measured by 5 observers in 10 consecutive patients. Measurements were performed on hard copy using a ruler and on a workstation using an electronic caliper. RESULTS: the intraobserver variability showed a decrease going from hard copy to workstation in the standard deviation of the differences of the paired observations for the neck from 3.54 mm to 1.18 mm; for the aorta from 4.16 to 1.72 mm; for the right iliac from 1.87 to 1.01 mm; for the left iliac from 2.07 to 0.87 mm. The interobserver variability showed a similar decrease for the neck in all ten pairs of observers; for the aorta in two, for the right iliac and left iliac in five. However, the difference between observers regularly exceeded 2 mm. CONCLUSION: the use of a workstation and electronic calipers results in lower intra- and interobserver variability. However, the results still show a clinically relevant difference between the observers. Therefore, it is necessary to develop an automatic observer-independent measurement technique.  (+info)

(3/131) The risk of contrast media-induced ventricular fibrillation is low in canine coronary arteriography with ioxilan.

Previous studies have proposed that sodium supplement to nonionic contrast media (CM) can decrease the risk of ventricular fibrillation (VF). This study was designed to compare the occurence of VF induced by ioxilan (containing 9 mmol/LNa+) with other nonionic CMs. After wedging a catheter in the right coronary artery, test solutions including ioxilan, ioversol, iomeprol, and iopromide were infused for 30 sec at the rate of 0.4 ml/sec or until VF occurred. Then, incidence of VF, contact time (i.e. the time required to produce VF), and QTc were measured. Also, the CMs other than ioxilan were investigated at sodium levels adjusted to 9 and 20 mmol/L Na+. The incidence of VF with ioxilan (0%) was the lowest of all. In the other CMs, the incidence decreased in accordance with increase of sodium. Iomeprol and iopromide showed significant reduction of VF incidence at the sodium level of 20 mmol/L. The higher sodium supplements also prolonged the contact times. The increase of QTc was the greatest in ioxilan. Ioxilan has the least arrythmogenic property among the current low-osmolality nonionic CMs. This property might be attributable to an optimal sodium concentration of 9 mmol/L in the CM.  (+info)

(4/131) Descending aorta wall volume and coronary artery disease: a comparative study using enhanced computed tomography of the chest and coronary angiography.

The study examined the association between aortic wall volume (AWV) detected by enhanced computed tomography and coronary artery atherosclerosis observed on angiography. In 180 cases, AWV was measured as the total wall volume of a 7-cm portion of the descending thoracic aorta distal from the tracheal bifurcation. Coronary artery atherosclerosis was angiographically quantified by both Gensini score, in terms of the severity of coronary artery stenosis, and Extent score, in terms of the severity of coronary artery involvement. Mean AWV values between the patients with significant coronary artery stenosis and those without significant stenosis were 9.83+/-4.04 cm3 and 8.09+/-2.39 cm3, respectively (p<0.001). AWV was a significantly independent variable for significant coronary artery disease (p=0.0097) and an Extent score > or = 60 (p=0.0092). Calcification of AWV, however, was not associated with coronary atherosclerosis. The quantification of aortic atherosclerosis was useful for diagnosing coronary artery disease.  (+info)

(5/131) Proximal tubule cell response to radiographic contrast media.

Renal dysfunction associated with contrast media (CM) administration is generally attributed to reduced renal blood flow. Studies, however, also suggest direct tubular effects of CM, whose mechanisms remain unclear. This study was conducted to assess the chemotoxic effects of iopamidol, a prototypic CM, on a porcine proximal tubule (PT) cell line, LLC-PK(1) cells. Results indicate that iopamidol did not affect cell viability (determined by trypan blue exclusion and fluorescein staining), but did reduce cell proliferation. Moreover, iopamidol altered mitochondrial function, as determined by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction and mitochondrial membrane potential. Decreased MTT reduction was evident with all CM tested, and its rapid recovery after CM removal suggests that inhibition of mitochondrial function is reversible. Injury to PT cells by iopamidol is supported by the fact that CM increase extracellular adenosine, an indicator of cellular stress. This study provides greater insight into the mechanism underlying the nephrotoxicity induced by contrast in patients and explains the reversibility of this toxicity.  (+info)

(6/131) Postinfarctional remodeling: increased dye intensity in the myocardial risk area after angioplasty of infarct-related coronary artery is associated with reduction of ventricular volumes.

OBJECTIVES: We sought to evaluate if angiographic dye videointensity of the risk area during percutaneous transluminal coronary angioplasty (PTCA) of the infarct-related artery (IRA) relates to remodeling. BACKGROUND: Poor reflow after myocardial infarction (MI) predicts worse ventricular remodeling. METHODS: Fifty-three patients with a first anterior MI and isolated disease of the left anterior descending (LAD), who underwent "primary" (n = 14), "rescue" (n = 7) or "late" (after 10 +/- 4 days, n = 32) PTCA, were retrospectively selected. In 10 patients prospectively collected, we assessed Doppler flow velocities and Doppler flow reserve (DFR), relating them to the videointensity technique. Coronary stenosis and TIMI flow were determined, and echocardiographic volumes (end-diastolic and end-systolic volume indexes) and regional asynergy were computed before hospital discharge (baseline) and at six months. Assuming higher peak videointensity reflects greater myocardial blood volume, a 1- to 5-point (poor-optimal) perfusion scale was devised. RESULTS: The correlation of Doppler peak velocity and DFR with videointensity was significant (r = 0.58, p = 0.007 and r = 0.71, p < 0.001, respectively). Patients were subdivided into group A (increased videointensity post-PTCA > or = 1.5 points, n = 29) and group B (unchanged videointensity, n = 24). Analysis of variance showed a time-group interaction for end-diastolic volume index (-4.6 +/- 23% vs. +22 +/- 22%, p = 0.003) and end-systolic volume index (-3.05 +/- 11.1% vs. +4.1 +/- 12.5%, p = 0.027). There was no interaction for changes in LAD stenosis (p = 0.39) and TIMI flow after PTCA (p = 0.27), or regional asynergy at six months (p = 0.31). CONCLUSIONS: Angiographic dye videointensity in the risk area correlates with Doppler peak velocity and DFR, and its increase after PTCA of IRA has a limiting effect on ventricular volumes, independent of coronary stenosis resolution, changes in Thrombolysis In Myocardial Infarction (TIMI) flow or extent of regional asynergy.  (+info)

(7/131) Effects of nonionic contrast media on platelet aggregation: assessment by particle counting with laser-light scattering.

Intravascular radiographic contrast media used in angiography, particularly nonionic contrast media, may cause activation of platelets. This study was designed to determine which properties of nonionic contrast media were potentially responsible for this action. Platelet aggregation after adenosine diphosphate stimulation was studied in the platelet rich plasma obtained from 37 patients who underwent left ventriculography using the highly sensitive method of particle counting with laser-light scattering. Platelet activation by contrast media was studied in the platelet rich plasma from healthy volunteers using flow cytometric analysis to detect platelet degranulation as P-selectin expression. There was a significant decrease in platelet aggregation in patients injected with ioxilan or iomeprol compared with patients injected with iohexol. There was a significant increase in P-selectin expression with the three groups of contrast media compared to control. The platelet activation with ioxilan or iomeprol was significantly less compared to the activation with iohexol. The comparison showed that previous generalization regarding platelet activation by nonionic contrast media might not be valid. It is presumed that the higher osmolality of iohexol may contribute to the increase in platelet aggregation and activation.  (+info)

(8/131) Assessment of Fallopian tube patency by HyCoSy: comparison of a positive contrast agent with saline solution.

OBJECTIVE: To compare the efficiency of air-filled albumin microspheres (Infoson) with saline solution in determining Fallopian tube patency during hysterosalpingo contrast sonography (HyCoSy). METHODS: This was a prospective randomized multicenter study with a sequential design. Over a 10-month period, 23 patients (mean age, 33 years) referred for infertility were examined by HyCoSy (saline or Infoson) before conventional hysterosalpingography (Iopamiron 370), performed during the same session. Contrast agents were administered through a 5-F Ackrad balloon catheter inserted transcervically into the uterine cavity. HyCoSy was performed with a 7-MHz transvaginal probe using both B-mode and color Doppler, and tubal patency was demonstrated by the appearance of contrast agent in the peritoneal cavity near the ovaries. Data were registered for each patient during the examination and the results were monitored by sequential analysis. RESULTS: Mean volumes of contrast injections were 35.3 mL of saline, 14.4 mL of Infoson, and 13.8 mL of Iopamiron 370. Infoson-enhanced HyCoSy provided a significantly larger (P = 0.006) number of correct diagnoses (20/22 Fallopian tubes) than did saline HyCoSy (12/24 Fallopian tubes), and the same number as that achieved by hysterosalpingography. CONCLUSION: A positive ultrasound contrast agent appears to be more efficient than saline solution at determining Fallopian tube patency in infertile women by means of HyCoSy, and as efficient as an iodinated contrast agent in the same population explored by HSG. HyCoSy could be used to screen infertile women, thereby avoiding the use of iodinated contrast medium and exposure to ionizing radiation during conventional HSG in patients with patent Fallopian tubes.  (+info)



  • Injection
  • Iopamidol-300 (Iopamidol Injection, USP) 61%, 150 mL in a 200 mL vial, Single Dose, Rx for intravascular use for angiography throughout the cardiovascular system and intravenous adult and pediatric contrast enhancement of computed tomographic head and body imaging. (safetyalerts.com)
  • Iopromide
  • Intralipid (intravenous Fat Emulsion) Iohexol Sterile Solution Iopamidol Sterile Solution Iopromide Iron Preparation for parenteral use Isocarboxazid Isoflurane Isonicotinic acid hydrazine and other hydrazine detivatives of isonicotinic acid, their derivatives, their salts. (wikipedia.org)
  • PRODUCT
  • In 1981 the company launched Iopamidol in Italy and Germany, a product with outstanding tolerability, whose stability allowed it to be stored in phials for unlimited periods of time. (wikipedia.org)